Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma

Nizar J. Bahlis, Jennifer McCafferty-Grad, Ileana Jordan-McMurry, Jim Neil, Isildinha Reis, Mohamed Kharfan-Dabaja, James Eckman, Mark Goodman, Hugo F. Fernandez, Lawrence H. Boise, Kelvin P. Lee

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Patients with multiple myeloma (MM) invariably relapse with chemotherapy-resistant disease, underscoring the need for new agents that bypass these resistance mechanisms. We have reported that ascorbic acid (AA) enhances the activity of arsenic trioxide (As203) against drug-resistant MM in vitro by depleting intracellular glutathione (GSH). These data led us to open a National Cancer Institute/Cancer Therapy Evaluation Program-sponsored Phase I/II trial of AS203 + AA for relapsed/refractory MM. We now present the completed Phase I component of this trial. The primary objective of the trial's Phase I component was to assess whether the addition of AA affected the well-described toxicity profile of As203 alone. Correlative studies were undertaken of As203 and AA pharmacokinetics, the ability of AA to deplete intracellular GSH in vivo, and the development of arsenic resistance. Six patients with stage IIIA relapsed/refractory myeloma were studied. We found that 0.25 mg/kg/day As2O3 + 1000 mg/day AA could be given for 25 days (over a 35-day period) without dose-limiting toxicity. One episode of grade 3 hematological toxicity (leukopenia) and no grade 3 nonhematological toxicities (in particular, cardiac) were observed. The coadministration of AA did not alter the pharmacokinetics of As203, and elevated AA levels were associated with decreased intracellular GSH. Serial in vitro studies demonstrated continued sensitivity of patient myeloma cells to As203 + AA. Two patients (both with thalidomide-refractory disease) had partial responses; four patients had stable disease. In conclusion, we have found that As203 + AA has acceptable toxicity and that there is promising evidence of activity in refractory/relapsed myeloma.

Original languageEnglish
Pages (from-to)3658-3668
Number of pages11
JournalClinical Cancer Research
Volume8
Issue number12
StatePublished - Dec 1 2002

Fingerprint

Multiple Myeloma
Ascorbic Acid
Glutathione
Therapeutics
Pharmacokinetics
arsenic trioxide
Thalidomide
National Cancer Institute (U.S.)
Leukopenia
Program Evaluation
Arsenic
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. / Bahlis, Nizar J.; McCafferty-Grad, Jennifer; Jordan-McMurry, Ileana; Neil, Jim; Reis, Isildinha; Kharfan-Dabaja, Mohamed; Eckman, James; Goodman, Mark; Fernandez, Hugo F.; Boise, Lawrence H.; Lee, Kelvin P.

In: Clinical Cancer Research, Vol. 8, No. 12, 01.12.2002, p. 3658-3668.

Research output: Contribution to journalArticle

Bahlis, NJ, McCafferty-Grad, J, Jordan-McMurry, I, Neil, J, Reis, I, Kharfan-Dabaja, M, Eckman, J, Goodman, M, Fernandez, HF, Boise, LH & Lee, KP 2002, 'Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma', Clinical Cancer Research, vol. 8, no. 12, pp. 3658-3668.
Bahlis, Nizar J. ; McCafferty-Grad, Jennifer ; Jordan-McMurry, Ileana ; Neil, Jim ; Reis, Isildinha ; Kharfan-Dabaja, Mohamed ; Eckman, James ; Goodman, Mark ; Fernandez, Hugo F. ; Boise, Lawrence H. ; Lee, Kelvin P. / Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 12. pp. 3658-3668.
@article{6b5516a680294f1a89d903dd141281a8,
title = "Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma",
abstract = "Patients with multiple myeloma (MM) invariably relapse with chemotherapy-resistant disease, underscoring the need for new agents that bypass these resistance mechanisms. We have reported that ascorbic acid (AA) enhances the activity of arsenic trioxide (As203) against drug-resistant MM in vitro by depleting intracellular glutathione (GSH). These data led us to open a National Cancer Institute/Cancer Therapy Evaluation Program-sponsored Phase I/II trial of AS203 + AA for relapsed/refractory MM. We now present the completed Phase I component of this trial. The primary objective of the trial's Phase I component was to assess whether the addition of AA affected the well-described toxicity profile of As203 alone. Correlative studies were undertaken of As203 and AA pharmacokinetics, the ability of AA to deplete intracellular GSH in vivo, and the development of arsenic resistance. Six patients with stage IIIA relapsed/refractory myeloma were studied. We found that 0.25 mg/kg/day As2O3 + 1000 mg/day AA could be given for 25 days (over a 35-day period) without dose-limiting toxicity. One episode of grade 3 hematological toxicity (leukopenia) and no grade 3 nonhematological toxicities (in particular, cardiac) were observed. The coadministration of AA did not alter the pharmacokinetics of As203, and elevated AA levels were associated with decreased intracellular GSH. Serial in vitro studies demonstrated continued sensitivity of patient myeloma cells to As203 + AA. Two patients (both with thalidomide-refractory disease) had partial responses; four patients had stable disease. In conclusion, we have found that As203 + AA has acceptable toxicity and that there is promising evidence of activity in refractory/relapsed myeloma.",
author = "Bahlis, {Nizar J.} and Jennifer McCafferty-Grad and Ileana Jordan-McMurry and Jim Neil and Isildinha Reis and Mohamed Kharfan-Dabaja and James Eckman and Mark Goodman and Fernandez, {Hugo F.} and Boise, {Lawrence H.} and Lee, {Kelvin P.}",
year = "2002",
month = "12",
day = "1",
language = "English",
volume = "8",
pages = "3658--3668",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma

AU - Bahlis, Nizar J.

AU - McCafferty-Grad, Jennifer

AU - Jordan-McMurry, Ileana

AU - Neil, Jim

AU - Reis, Isildinha

AU - Kharfan-Dabaja, Mohamed

AU - Eckman, James

AU - Goodman, Mark

AU - Fernandez, Hugo F.

AU - Boise, Lawrence H.

AU - Lee, Kelvin P.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Patients with multiple myeloma (MM) invariably relapse with chemotherapy-resistant disease, underscoring the need for new agents that bypass these resistance mechanisms. We have reported that ascorbic acid (AA) enhances the activity of arsenic trioxide (As203) against drug-resistant MM in vitro by depleting intracellular glutathione (GSH). These data led us to open a National Cancer Institute/Cancer Therapy Evaluation Program-sponsored Phase I/II trial of AS203 + AA for relapsed/refractory MM. We now present the completed Phase I component of this trial. The primary objective of the trial's Phase I component was to assess whether the addition of AA affected the well-described toxicity profile of As203 alone. Correlative studies were undertaken of As203 and AA pharmacokinetics, the ability of AA to deplete intracellular GSH in vivo, and the development of arsenic resistance. Six patients with stage IIIA relapsed/refractory myeloma were studied. We found that 0.25 mg/kg/day As2O3 + 1000 mg/day AA could be given for 25 days (over a 35-day period) without dose-limiting toxicity. One episode of grade 3 hematological toxicity (leukopenia) and no grade 3 nonhematological toxicities (in particular, cardiac) were observed. The coadministration of AA did not alter the pharmacokinetics of As203, and elevated AA levels were associated with decreased intracellular GSH. Serial in vitro studies demonstrated continued sensitivity of patient myeloma cells to As203 + AA. Two patients (both with thalidomide-refractory disease) had partial responses; four patients had stable disease. In conclusion, we have found that As203 + AA has acceptable toxicity and that there is promising evidence of activity in refractory/relapsed myeloma.

AB - Patients with multiple myeloma (MM) invariably relapse with chemotherapy-resistant disease, underscoring the need for new agents that bypass these resistance mechanisms. We have reported that ascorbic acid (AA) enhances the activity of arsenic trioxide (As203) against drug-resistant MM in vitro by depleting intracellular glutathione (GSH). These data led us to open a National Cancer Institute/Cancer Therapy Evaluation Program-sponsored Phase I/II trial of AS203 + AA for relapsed/refractory MM. We now present the completed Phase I component of this trial. The primary objective of the trial's Phase I component was to assess whether the addition of AA affected the well-described toxicity profile of As203 alone. Correlative studies were undertaken of As203 and AA pharmacokinetics, the ability of AA to deplete intracellular GSH in vivo, and the development of arsenic resistance. Six patients with stage IIIA relapsed/refractory myeloma were studied. We found that 0.25 mg/kg/day As2O3 + 1000 mg/day AA could be given for 25 days (over a 35-day period) without dose-limiting toxicity. One episode of grade 3 hematological toxicity (leukopenia) and no grade 3 nonhematological toxicities (in particular, cardiac) were observed. The coadministration of AA did not alter the pharmacokinetics of As203, and elevated AA levels were associated with decreased intracellular GSH. Serial in vitro studies demonstrated continued sensitivity of patient myeloma cells to As203 + AA. Two patients (both with thalidomide-refractory disease) had partial responses; four patients had stable disease. In conclusion, we have found that As203 + AA has acceptable toxicity and that there is promising evidence of activity in refractory/relapsed myeloma.

UR - http://www.scopus.com/inward/record.url?scp=0036896388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036896388&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 3658

EP - 3668

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -